Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Leukemia
•
Hematology
How would you approach a young, fit patient with suspected CNS involvement with high circulating blasts?
What induction and IT regimens do you use for patients with confirmed AML with CNS involvement?
Related Questions
How does the CLL17 trial presented at ASH 2025 change current practice guidelines?
In patients with AML who achieve a CR with HMA/Ven, what is the optimal dose and schedule for venetoclax for further cycles?
How do you approach neutropenia in patients being treated with obinutuzumab/venetoclax for CLL?
What induction regimen would you consider for KMT2A-rearranged AML in a young patient with multiple medical co-morbidities who is ineligible for clinical trials?
Do you routinely include bone marrow examination in your initial evaluation of a patient with chronic myeloid leukemia?
What is your preferred first-line treatment regimen for patients with high-risk MDS?
Is there therapeutic relevance for FLT3-ITD mutation in relapsed APML?
In treatment naive CLL without del(17p)/TP53, will the recent interim analysis of fixed duration acalabrutinib plus venetoclax +/- obinutuzumab vs chemoimmunotherapy in the AMPLIFY trial change your practice?
Would you give GO and/or a FLT3 inhibitor for patients with AML with t(8;21) and FLT3-ITD low in addition to 7+3?
In patients with post-PV myelofibrosis who are ineligible for allogeneic stem cell transplant, how do you approach symptomatic splenomegaly refractory to splenic radiation and ruxolitinib?